αααααβααΎαNOVO-B β’ CPH
add
Novo Nordisk A/S
490.35Β kr
6 αα·αα»ααΆ, 8:58:55 PM ααααβααα +2 · DKK · CPH · ααα
ααααΈαααααΆααα·αααα½ααα»αααααΌα
ααΆαβα αα»αααΌααααααααααΆαα
α»ααααααΈαα
DKααΆαααΈααααΆααααΆααααααΆααα
DK
αα·αααΈαα»α
476.70Β kr
α
αααααααααααα
480.85Β kr - 492.90Β kr
α
ααααααα½αααααΆαα
α»αααααα
380.00Β kr - 1,033.20Β kr
ααΎαβαα»αβααΈααααΆα
1.66Β ααααΈααΆα DKK
ααα ααα½αααΌαααααα
5.64Β ααΆα
α’αα»ααΆα P/E
-
αα·αααααβααΆαααΆα
-
ααΆααααααΌαα
αααα
CPH
αααα»αβααααααΆαβ
α α·ααααααααα»
αααΆαααΆαααααααΆααα
αααΌα
α
αααΌα
α
αααΌααα»ααα
(DKK) | ααΈααΆ 2025info | ααΆαααααΆααααααΌαααΆαβααααΆα |
---|---|---|
α
αααΌα | 78.09Β αααΈααΆα | 19.49% |
α
αααΆαααααα·ααααα·ααΆα | 26.41Β αααΈααΆα | 11.95% |
α
αααΌααα»ααα | 29.03Β αααΈααΆα | 14.28% |
ααααΆααα
αααααα»ααα | 37.18 | -4.37% |
βα
αααΌααα»αααβαααα»ααα½αααΆαα αα»α | 6.53 | 14.96% |
α
αααΌααα»ααααα»αααΆαααααΆαα αααα ααΆαααααα αα·αααΆαααΆααααααα | 42.62Β αααΈααΆα | 25.34% |
α’ααααΆαααααααααΆαααααα·αααααΆα | 21.60% | β |
αααααΈαααα»ααα
ααααααααα»α
ααΆαααα½ααα»αααααΌαααα»α
(DKK) | ααΈααΆ 2025info | ααΆαααααΆααααααΌαααΆαβααααΆα |
---|---|---|
ααΆα
αααααΆαα αα·αααΆααα·αα·αααααααααααααΈ | 41.55Β αααΈααΆα | 346.63% |
ααααααααα»α | 489.16Β αααΈααΆα | 63.64% |
ααΆαααα½ααα»αααααΌαααα»α | 350.62Β αααΈααΆα | 75.30% |
ααΌαβααααα»α | 138.54Β αααΈααΆα | β |
ααΆαα αα»αβαα·αβααΆααααΆαααα | 4.44Β αααΈααΆα | β |
ααααααααααΉαααααα
| 15.27 | β |
ααα
ααααααΎαααααα | 20.31% | β |
ααα
ααααααΎααΎααα»α | 38.52% | β |
ααα αΌαβααΆα
αβααααΆααβ
ααΆααααααααα½αβααΆα
αααααΆαααα»ααα
(DKK) | ααΈααΆ 2025info | ααΆαααααΆααααααΌαααΆαβααααΆα |
---|---|---|
α
αααΌααα»ααα | 29.03Β αααΈααΆα | 14.28% |
ααΆα
αααααΆααααΈααααα·ααααα·ααΆα | 24.59Β αααΈααΆα | 71.80% |
ααΆα
αααααΆααααΈααΆααα·αα·ααα | -6.67Β αααΈααΆα | -268.68% |
ααΆα
αααααΆααααΈα α·ααααβαααααΆα | 5.45Β αααΈααΆα | 120.66% |
ααΆααααααααα½αβααΆα
αααααΆαααα»ααα | 23.28Β αααΈααΆα | 388.58% |
ααα αΌαααΆα
αααααΆααααααα | 22.11Β αααΈααΆα | 247.28% |
α’αααΈ
Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, with production facilities in nine countries and affiliates or offices in five. Novo Nordisk is controlled by majority shareholder Novo Holdings A/S which holds approximately 28.1% of its shares and a majority of its voting shares.
Novo Nordisk manufactures and markets pharmaceutical products and services, specifically diabetes care medications and devices. Novo Nordisk makes the drug semaglutide, used to treat diabetes under the brand names Ozempic and Rybelsus and obesity under the brand name Wegovy. Novo Nordisk is also involved with hemostasis management, growth hormone therapy, and hormone replacement therapy. The company makes several drugs under various brand names, including Levemir, Tresiba, NovoLog, Novolin R, NovoSeven, NovoEight, and Victoza.
Novo Nordisk employs more than 48,000 people globally, and markets its products in 168 countries. The corporation was created in 1989, through a merger of two Danish companies, which date back to the 1920s. The Novo Nordisk logo is the Apis bull, one of the sacred animals of ancient Egypt, denoted by the hieroglyph π. Wikipedia
ααΆααααααΎαα‘αΎα
21 ααααΌ 1923
ααΆαα·ααΆαααβαααααΆα
αααααβαααααΆα
αα»ααααα·α
77,406